ModernaTX, Inc. $MRNA
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS14
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO60%
Delay Index: of 10 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +25.1 months). See all sponsors →
Open ModernaTX, Inc. on the live radar map → 📅 $MRNA readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| mRNA-1189 NCT05164094 |
P1/2 | Active, not recruiting | Epstein-Barr Virus Infection | 867 | 2026-10-05 (+39 mo) |
| mRNA-3745 NCT05095727 |
P1/2 | Active, not recruiting | Glycogen Storage Disease | 15 | 2026-11-30 (+34 mo) |
| mRNA-1018-H5 NCT07496450 |
P3 | Active, not recruiting | Influenza | 4050 | 2027-01-28 |
| Nova 301 NCT06592794 |
P3 | Active, not recruiting | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | 37864 | 2027-02-15 (-3 mo) |
| mRNA-1647 NCT05683457 |
P2 | Active, not recruiting | Cytomegalovirus Infection | 84 | 2027-03-06 (+25 mo) |
| mRNA-3927 NCT04159103 |
P1/2 | Recruiting | Propionic Acidemia | 77 | 2027-08-31 (+51 mo) |
| mRNA-1982 NCT07561294 |
P2 | Active, not recruiting | Lyme Disease | 366 | 2028-11-09 |
| mRNA-1195 NCT06735248 |
P2 | Recruiting | Multiple Sclerosis | 180 | 2029-01-08 |
| mRNA-1283 NCT07808697 |
P2 | Recruiting | SARS-CoV-2 | 300 | 2029-08-30 |
| mRNA-3927 NCT05130437 |
P1/2 | Recruiting | Propionic Acidemia | 50 | 2029-12-04 |
| mRNA-2808 NCT07116616 |
P1/2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 190 | 2030-06-17 |
| mRNA-4359 NCT05533697 |
P1/2 | Recruiting | Advanced Solid Tumors | 361 | 2032-02-18 (+50 mo) |
| mRNA-4157 NCT03897881 |
P2 | Active, not recruiting | Melanoma | 267 | 2032-11-21 |
| mRNA-3705 NCT05295433 |
P1/2 | Recruiting | Methylmalonic Acidemia | 56 | 2034-04-02 (+24 mo) |